Desfechos de longo prazo de pacientes com metástase cerebral ativa de melanoma tratados com a combinação nivolumabe e ipilimumabe.

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Estudo original: Study: Combination Immunotherapy for Melanoma Brain Metastases

Conteúdo relacionado: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma